Mirikizumab – the first anti-IL23 p19 antibody in ulcerative colitis therapy
Drug profileGastroent Hepatol 2024; 78(1): 27–30. doi: 10.48095/ccgh202427
Literaturepdf Milan LukášFilgotinib in the treatment of inflammatory bowel diseases
Drug profileGastroent Hepatol 2023; 77(2): 145–146. doi: 10.48095/ccgh2023145
Literaturepdf Milan LukášTitanlax – medical device profile
Drug profileGastroent Hepatol 2022; 76(6): 519–521. doi: 10.48095/ccgh2022519
SummaryLiteraturepdf Vilma VranováDificlir – fidaxomicin – an effective treatment option for C. difficile infections in children
Drug profileGastroent Hepatol 2022; 76(6): 515–516. doi: 10.48095/ccgh2022515
Literaturepdf Kristýna ZárubováLow-volume polyethylene glycol ascorbate solution (PLENVUTM) – a new generation of intestinal cleansers with high efficiency and good tolerance
Drug profileGastroent Hepatol 2022; 76(2): 153–154. doi: 10.48095/ccgh2022153
Literaturepdf Milan LukášRemsima SC 120 mg – a new generation of biosimilar drugs
Drug profileGastroent Hepatol 2022; 76(1): 57–59. doi: 10.48095/ccgh202257
Literaturepdf Milan LukášTeduglutide, a glucagon-like peptide-2 analogue (REVESTIVE), in the treatment of short bowel syndrome with dependence on home parenteral nutrition
Drug profileGastroent Hepatol 2021; 75(2): 170–172. doi: 10.48095/ccgh2021170
Literaturepdf František NovákRifaximin in therapy of inflammatory bowel disease
Drug profileGastroent Hepatol 2021; 75(1): 51–54. doi: 10.48095/ccgh202151
Literaturepdf Milan LukášSubcutaneous vedolizumab treatment for ulcerative colitis and Crohn‘s disease in clinical trial VISIBLE
Drug profileGastroent Hepatol 2020; 74(6): 558–561. doi: 10.48095/ccgh2020558
LiteraturepdfBudesonide in the treatment of idiopathic intestinal inflammation
Drug profileGastroent Hepatol 2020; 74(5): 449–451. doi:10.14735/amgh2020449
Literaturepdf Milan Lukáš